OKYO Pharma logo
OKYO Pharma
OKYO | NASDAQ
Chart Builder DCF Calculator
$1.18
-$0.17 (-12.59%)
At close: Nov 16, 2026, 4:00 PM ET
$1.18
$0.00 (-0.42%)
After-hours: Nov 16, 2026, 4:26 PM ET

OKYO Pharma Company Profile

Company profile explained

Company Profile

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Key Executives

Name Position
Robert J. Dempsey Chief Executive Officer & Executive Director
Keeren Shah Chief Financial Officer
Flavio Mantelli Chief Medical Officer
Gary S. Jacob Chief Development Officer & Director
Michael Paul Beck Founder
Rajkumar Patil Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 06, 2026 6-K Filing
Sep 29, 2026 6-K Filing
Sep 09, 2026 6-K Filing
Sep 08, 2026 6-K Filing
Aug 07, 2026 20-F/A [Amend] Filing
Aug 07, 2026 4/A [Amend] Filing
Aug 07, 2026 4/A [Amend] Filing
Aug 07, 2026 4/A [Amend] Filing
Aug 07, 2026 4/A [Amend] Filing
Aug 07, 2026 4/A [Amend] Filing
View All SEC Filings ➞
OKYO Pharma
OKYO Pharma logo
Country United Kingdom
IPO Date May 17, 2022
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Robert J. Dempsey

Contact Details

35a Albemarle St London, GL W1S 4JE United Kingdom

Stock Details

Ticker Symbol OKYO
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001849296
CUSIP Number G6724L116
ISIN Number GG00BMFG5F62
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.